Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2024年8月6日 - 9:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 6, 2024
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Novo
Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 06 August
2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014
of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016
(the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be
executed during a 12-month period beginning 6 February 2024.
Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B shares for an
amount up to DKK 2.2 billion in the period from 7 May 2024 to 5 August 2024. The programme is now concluded.
Since the announcement 29 July 2024, the following transactions have been made:
|
Number of
B shares |
Average
purchase price |
Transaction
value, DKK |
Accumulated, last announcement |
2,086,287 |
|
1,980,536,332 |
29 July 2024 |
41,481 |
881.68 |
36,572,943 |
30 July 2024 |
41,500 |
902.86 |
37,468,894 |
31 July 2024 |
40,600 |
908.33 |
36,878,217 |
1 August 2024 |
39,708 |
912.52 |
36,234,465 |
2 August 2024 |
40,000 |
893.49 |
35,739,564 |
5 August 2024 |
43,300 |
843.90 |
36,540,863 |
Accumulated under the programme |
2,332,876 |
|
2,199,971,278 |
The details for each transaction made under the share repurchase programme are published on
novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of 12,432,916 B shares of
DKK 0.10 as treasury shares, corresponding to 0.3% of the share capital. The total amount of A and B shares in the company is
4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-
month period beginning 6 February 2024. As of 05 August 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 11,067,126
B shares at an average share price of DKK 878.97 per B share equal to a transaction value of DKK 9,727,706,050.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering
scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs
about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen
(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram,
X, LinkedIn and YouTube.
Contact for further information.
Media: |
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
|
|
Investors: |
|
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
|
|
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
Sina Meyer
+45 3079 6656
azey@novonordisk.com |
|
|
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com |
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com CVR no: 24 25 67 90 |
| | | Company
announcement No 57 / 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 6, 2024 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
過去 株価チャート
から 8 2024 まで 9 2024
Novo Nordisk (PK) (USOTC:NONOF)
過去 株価チャート
から 9 2023 まで 9 2024